Leadless pacemakers will likely become a more common and preferred option for patients with heart rhythm disorders. Credit: Birgit Reitz-Hofmann via Shutterstock.

Unlike traditional pacemakers, which possess leads – wires that must be placed inside the chambers of the heart, leadless pacemakers reduce complications, simplify the implantation process, and enhance patient comfort. The dual chamber leadless pacemaker market is set to grow in value at a compound annual growth rate (CAGR) of 7.9% between 2024 and 2033 while the market value of traditional dual chamber pacemakers is forecast to grow at a CAGR of 2.7%.

For years, Medtronic was the only manufacturer of leadless pacemakers with its Micra product line. However, since Abbott’s release of its AVEIR leadless pacemaker family, the market dynamics in the pacemaker space have shifted.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In July 2023, Abbott received FDA approval for its AVEIR DR dual chamber leadless pacemaker system. Unlike Medtronic’s version of a dual chamber leadless pacemaker, the Micra AV2, which can only deliver ventricular therapy, the AVEIR DR can achieve both ventricular and atrial therapy. Additionally, because of the AVEIR DR’s reported higher ease of retrievability, it will likely become the pacemaker of choice for younger patients, who are more likely to receive a replacement sometime in their lifetime.

By strategically expanding into areas that the Micra AV2 was not able to, Abbott successfully gained market share from Medtronic. The Micra AV2 can only address about 50% of the needs in the pacemaker market while Abbott’s AVEIR DR can cover approximately 95% of the indications in the space, and potentially even more.

Despite the number of advantages leadless pacemakers offer, widespread adoption of leadless pacemakers is hindered by a combination of cost, the need for specialised training for implantation, and the need for more long-term data. As these challenges are addressed, leadless pacemakers will likely become a more common and preferred option for patients with heart rhythm disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.